JPH1119178A - Manufacture of medical container containing medical solution with carbonic acid component - Google Patents
Manufacture of medical container containing medical solution with carbonic acid componentInfo
- Publication number
- JPH1119178A JPH1119178A JP9337812A JP33781297A JPH1119178A JP H1119178 A JPH1119178 A JP H1119178A JP 9337812 A JP9337812 A JP 9337812A JP 33781297 A JP33781297 A JP 33781297A JP H1119178 A JPH1119178 A JP H1119178A
- Authority
- JP
- Japan
- Prior art keywords
- carbonic acid
- acid component
- mother liquor
- solution
- medical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Package Specialized In Special Use (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、輸液、透析液、臓器保
存液等を収納した医療用容器の製造方法に関するもので
あり、特に、安定性に欠ける炭酸成分を含有させた医療
用溶液を収容した医療用容器の製造方法に関するもので
ある。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a method for producing a medical container containing an infusion solution, a dialysate, an organ preservation solution and the like, and more particularly to a medical solution containing a carbonic acid component lacking stability. The present invention relates to a method for manufacturing a contained medical container.
【0002】[0002]
【従来の技術】一般に重炭酸ナトリウム溶液を樹脂容器
等に収容すれば、加熱或いは保存中に分解し、炭酸ガス
が発生し、炭酸ガスは容器壁を透過して消失する。かか
る分解により溶液中には[OH-]が電離平衡のため増
加し、溶液のPH値は上昇する。このため、医療用容器
を長く保存するために、医療用容器をガスバリアー性の
包装体で密封包装し、包装体内に炭酸ガスを導入した
り、炭酸ガス発生型の脱酸素剤を配して医療用容器の外
側を炭酸ガス雰囲気とすることにより、樹脂容器内の炭
酸ガスが樹脂容器外にでることを阻止した技術が提案さ
れている(特許第2527532号公報、特開昭6−1
05905号公報)。2. Description of the Related Art Generally, when a sodium bicarbonate solution is contained in a resin container or the like, it is decomposed during heating or storage to generate carbon dioxide gas, and the carbon dioxide gas passes through the container wall and disappears. Due to such decomposition, [OH − ] increases in the solution due to ionization equilibrium, and the PH value of the solution increases. For this reason, in order to preserve the medical container for a long time, the medical container is hermetically sealed in a gas-barrier package, and carbon dioxide is introduced into the package or a carbon dioxide-generating type oxygen absorber is disposed. A technique has been proposed in which the carbon dioxide gas inside the resin container is prevented from flowing out of the resin container by setting the outside of the medical container to a carbon dioxide gas atmosphere (Japanese Patent No. 2527532, Japanese Unexamined Patent Application Publication No. Sho 6-1).
05905).
【0003】[0003]
【発明が解決しようとする課題】しかしながら、従来の
炭酸成分を含有した医療用容器の製造方法には以下の点
で問題が見られる。包装体に炭酸ガスを収容したもの
も、或いは脱酸素剤を配したものもにあっては、医療用
容器内の溶液の初期PH値は蒸気滅菌処理時の炭酸イオ
ンの喪失を防止するため8.32或いは8.60と高
い。そして、10日後以降に医療用容器内のPH値が
8.0以下を示す。これは、医療用容器内の溶液が包装
体内に存在し且つ容器壁を透過してくる炭酸ガスを取り
込んだものと考えられる。しかし、このような医療用容
器にあっては、初期組成から明らかに相違し、どの程度
の炭酸ガスが医療用容器内の溶液に溶け込んだか不明で
ある。また、炭酸ガスを過剰に取り込んだ溶液では溶液
中のカルシウムイオンやマグネシウムイオンと反応して
沈殿物を生じるおそれがある。従って、本発明は製造
前、製造後、或いは長期保存後のどの段階であってもP
H値がほぼ一定に維持され、且つ炭酸ガス濃度も一定に
維持される炭酸成分入り医療用溶液を収容した医療用容
器の製造方法を提供することにある。However, the conventional method for producing a medical container containing a carbonic acid component has the following problems. Regarding the package containing carbon dioxide gas or the package containing an oxygen scavenger, the initial PH value of the solution in the medical container is set at 8 to prevent the loss of carbonate ions during steam sterilization. It is as high as .32 or 8.60. After 10 days, the PH value in the medical container shows 8.0 or less. This is considered to be because the solution in the medical container was present in the package and took in carbon dioxide gas that had permeated the container wall. However, in such a medical container, it is clearly different from the initial composition, and it is unclear how much carbon dioxide dissolved in the solution in the medical container. Further, in a solution in which carbon dioxide gas is excessively taken in, a solution may react with calcium ions or magnesium ions in the solution to form a precipitate. Therefore, the present invention is applicable to any phase before, after, or after long-term storage.
An object of the present invention is to provide a method for manufacturing a medical container containing a medical solution containing a carbonic acid component, in which the H value is maintained substantially constant and the carbon dioxide gas concentration is also maintained constant.
【0004】[0004]
【課題を解決するための手段】本発明は、一の室に重炭
酸又は炭酸の塩又は塩溶液から成る炭酸成分を液密に収
容し、他の室に炭酸成分以外の電解質からなる母液を液
密に収容したの後、上記炭酸成分及び母液を分けた状態
で蒸気滅菌処理し、該滅菌処理後に上記炭酸成分と母液
を混ぜてなる炭酸成分入り医療用溶液を収容した医療用
容器の製造方法を提供することにより、上記目的を達成
したものである。SUMMARY OF THE INVENTION According to the present invention, a carbonic acid component comprising a salt or a salt solution of bicarbonate or carbonic acid is contained in one chamber in a liquid-tight manner, and a mother liquor comprising an electrolyte other than the carbonic acid component is contained in another chamber. Production of a medical container containing a carbonated medical solution containing the carbonic acid component and the mother liquor after the liquid carbonate is stored in a liquid-tight manner and then subjected to steam sterilization with the carbonic acid component and the mother liquor separated. The object has been achieved by providing a method.
【0005】上記医療用容器は通常可撓性壁を有する樹
脂容器である。可撓性壁は撓むことにより容器内の容積
が容易に変化するものであれば良い。また容器壁は内容
物の確認できる程度に透明性を有することが望ましい。
容器内での薬剤の状態を確認する上で必要となるからで
ある。上記容器は、インフレーションフィルム、チュー
ブ、シート及びフィルムから成形したもの、押出成形、
射出成形、又はブロー成形したものである。樹脂容器の
樹脂素材としてはポリオレフィン系樹脂、塩化ビニル、
塩化ビニリデン系樹脂、ポリエステル系樹脂、ポリビニ
ルアルコール系樹脂、ポリアクリルニトリル系樹脂、ポ
リアクリル酸系樹脂、ポリアミド系樹脂等の汎用樹脂で
ある。また樹脂容器は単層又は多層で形成されていても
良い。樹脂容器内の薬剤と接触する最内層は、薬剤に影
響を与えない、また溶出物が生じない樹脂層であるある
ことが望ましい。このような樹脂としては、ポリオレフ
ィン系樹脂が望ましく、例えば、低、中、高−密度ポリ
エチレン、ポリプロピレン等の低級オレフィン樹脂等が
挙げられる。また、樹脂容器壁にはガスバリアー性層が
形成されていることが望ましい。特に、酸素等を容易に
透過しない層であることが望ましい。このようなガスバ
リアー性層としては、殆ど、又は全くガスを透過させな
いアルミニウム等の金属層や酸化珪素、酸化マグネシウ
ム、酸化チタン等の無機蒸着層であり、またポリ塩化ビ
ニリデン、ポリエステル、ナイロン、エチレン−ビニル
アルコール共重合体、フッ素系樹脂等のようにガスバリ
アー性の高い樹脂層である。ガスバリアー性層の酸素透
過量は40cc・20μ/m2・day・atm(温
度:20℃)以下、特に、30cc・20μ/m2・d
ay・atm以下、また好ましくは5cc・20μ/m
2・day・atm以下、更には1cc・20μ/m2・
day・atm以下であることが望ましい。また、樹脂
容器の壁は内部の薬剤が確認できる程度に透明性を有す
ることが望まれる。このため、ガスを全く透過させない
優れた機能を有する上記アルミニウム層等の金属層から
成る壁は少なくとも一部においてその金属層が剥離可能
に形成されていることが望ましい。かかる層を有した樹
脂容器においては高圧蒸気滅菌時に内部の薬剤の熱によ
る変質を十分に防止することができる。The medical container is usually a resin container having a flexible wall. The flexible wall may be any as long as the volume in the container is easily changed by bending. Further, it is desirable that the container wall has transparency to the extent that the contents can be confirmed.
This is because it is necessary to confirm the state of the medicine in the container. The above containers are blown films, tubes, sheets and those molded from films, extrusion molding,
Injection molding or blow molding. Polyolefin resin, vinyl chloride,
It is a general-purpose resin such as a vinylidene chloride resin, a polyester resin, a polyvinyl alcohol resin, a polyacrylonitrile resin, a polyacrylic resin, and a polyamide resin. Further, the resin container may be formed in a single layer or a multilayer. The innermost layer in contact with the drug in the resin container is desirably a resin layer that does not affect the drug and does not generate elutes. As such a resin, a polyolefin-based resin is desirable, and examples thereof include low-, middle-, and high-density lower-grade olefin resins such as polyethylene and polypropylene. It is desirable that a gas barrier layer is formed on the resin container wall. In particular, a layer that does not easily transmit oxygen or the like is desirable. Examples of such a gas barrier layer include a metal layer made of aluminum or the like which hardly transmits gas at all or an inorganic vapor-deposited layer made of silicon oxide, magnesium oxide, titanium oxide, etc., and polyvinylidene chloride, polyester, nylon, ethylene, and the like. -A resin layer having a high gas barrier property, such as a vinyl alcohol copolymer and a fluororesin. The oxygen permeation amount of the gas barrier layer is 40 cc · 20 μ / m 2 · day · atm (temperature: 20 ° C.) or less, particularly, 30 cc · 20 μ / m 2 · d
ay · atm or less, and preferably 5 cc · 20 μ / m
2・ day ・ atm or less, 1cc ・ 20μ / m 2・
It is desirably not more than day · atm. Further, it is desired that the wall of the resin container has such transparency that the medicine inside can be confirmed. For this reason, it is desirable that at least a part of the wall made of a metal layer such as the aluminum layer having an excellent function of not allowing gas to permeate at all be formed so that the metal layer can be peeled off. In the resin container having such a layer, the deterioration of the internal medicine by heat during the high-pressure steam sterilization can be sufficiently prevented.
【0006】上記炭酸成分と母液とを分けて液密充填し
蒸気滅菌処理する。炭酸成分と母液とを分けて液密に収
容するとは、上記炭酸成分と上記母液を個別に収容する
複数の室を有した樹脂製の容器を用いても良い。このよ
うな容器が複数の室に分割される場合には室と室とを隔
離する部分に容器壁越しの操作により室と室とを互いに
連通する連通手段を構成することが望ましい。かかる連
通手段とは、閉鎖型管の端部を容器壁越しに破断して該
管を連通管とするもの、隔離部分を挟持クリップ等で止
めたもの、或いは、隔離する部分を外側からの操作によ
り剥離可能なピールシール部とするもの等、その他公知
の無菌的連通が可能な手段である。また、上記炭酸成分
と上記母液とを別個の容器に収容してこれを接続した複
数容器とし、個々の容器を室としたものでも良い。容器
同士の接続には上記ピールシール部で構成した容器端部
同士を接続して使用時に容器越しの操作で連通可能な構
造となるもの、容器同士をそれ自体公知の連通針を備え
た連通手段で連通操作可能なもの等が挙げられる。尚、
容器が複数容器から構成されるものは、少なくとも一方
はガラス製の容器であっても良いが、好ましく樹脂製容
器同士から構成することが望ましい。また特に、複数の
室は容器越し及び包装体越しに連通過能なピールシール
部で形成或いは接続されている容器であることが望まし
い。The carbonic acid component and the mother liquor are separately filled in a liquid-tight manner and subjected to steam sterilization. To separately store the carbonate component and the mother liquor in a liquid-tight manner may use a resin container having a plurality of chambers for individually storing the carbonate component and the mother liquor. When such a container is divided into a plurality of chambers, it is desirable to form a communicating means for communicating the chambers with each other by an operation through the container wall at a portion separating the chambers from each other. Such communication means may be one in which the end of a closed tube is broken through the container wall to make the tube a communication tube, one in which an isolated portion is stopped with a clip or the like, or an operation in which the isolated portion is operated from outside. Other known means for enabling aseptic communication, such as a peel seal portion that can be peeled off. Alternatively, the carbonic acid component and the mother liquor may be housed in separate containers and connected to form a plurality of containers, each of which may be a chamber. The connection between the containers is such that the ends of the containers formed by the peel seal portion are connected to each other so as to be able to communicate by operation through the container at the time of use, and a communication means having a communication needle known per se between the containers. And those that can be communicated. still,
When the container is composed of a plurality of containers, at least one of the containers may be a glass container, but it is preferable that the containers are composed of resin containers. In particular, it is desirable that the plurality of chambers are containers formed or connected by a peel seal portion capable of continuous passage through the container and the package.
【0007】即ち、上記ピールシール部は弱シール部と
も称され、外部から室或いは容器を圧迫し、内部が一定
の昇圧状態になったときに剥離する隔離シール部であ
る。上記ピールシール部の剥離強度は、室内の圧が0.
01〜1.0Kgf/cm2、特に、0.05〜0.5
Kgf/cm2の昇圧で剥離する強度が望ましい。上記
範囲を下回る強度であれば、製造、運搬、保存時等の隔
離状態を保つための安全性に欠ける。上記範囲を上回る
強度であれば、用時に室と室同士の連通操作を容易にす
ることができなくなるおそれがある。樹脂容器の内層同
士のピールシールの形成或いは完全固着シールを形成す
る場合にはそれ自体公知の技術を用いることができ、こ
れらのシールを確実に異ならせて形成するためには、樹
脂容器の内層が異なる樹脂のブレンド物であることが望
ましい。特に、異なる樹脂は、熱溶融開始温度、或いは
ピカッド軟化点が異なり、相溶性のあまりない樹脂ブレ
ンド物からなることが望ましい。かかるブレンド物層を
有することより、同一の内層で、完全な密封シール接着
のシール温度条件設定が簡単にできる一方、ピールシー
ル接着のシール温度条件設定も簡単にできる。また、ピ
ールシール接着に求められるシール強度、即ち、使用時
の外力による易剥離性と、保存時に剥離が生じないシー
ル強度との関係を厳密に設定することができる。即ち、
内層に相溶性の異なる樹脂を溶融混合し、これをシート
状に成形することによって、ミクロ的に熱接着性の異な
る部分に分離した表面としたものである。そして、任意
の温度におけるそのシートの表面相互のミクロ的な部分
の熱溶融性を決めることにより、シール強度の強弱を正
確に付け、上記効果を容易に達成するものである。That is, the peel seal portion is also referred to as a weak seal portion, and is an isolation seal portion that presses against a chamber or a container from the outside and peels off when the inside is pressurized to a certain level. The peel strength of the peel seal portion is such that the indoor pressure is 0.
01 to 1.0 kgf / cm 2 , particularly 0.05 to 0.5
It is desirable to have a peeling strength at a pressure of Kgf / cm 2 . If the strength is lower than the above range, the safety for maintaining an isolated state at the time of production, transportation, storage and the like is lacking. If the strength exceeds the above range, there is a possibility that the communication operation between the rooms cannot be easily performed at the time of use. In the case of forming a peel seal between the inner layers of the resin container or forming a completely fixed seal, a technique known per se can be used. In order to form these seals surely different from each other, the inner layer of the resin container must be formed. Is desirably a blend of different resins. In particular, it is desirable that the different resins be made of resin blends having different hot-melting onset temperatures or Picad softening points and little compatibility. By having such a blended material layer, it is possible to easily set the sealing temperature conditions for complete hermetic seal bonding with the same inner layer, but also to easily set the sealing temperature conditions for peel seal bonding. Further, the relationship between the seal strength required for peel seal adhesion, that is, the easy peelability due to external force during use, and the seal strength that does not cause peeling during storage can be strictly set. That is,
The resin having different compatibility is melt-mixed in the inner layer and formed into a sheet to form a surface which is microscopically separated into portions having different thermal adhesiveness. Then, by determining the thermal fusibility of the microscopic portion between the surfaces of the sheet at an arbitrary temperature, the strength of the sealing strength is accurately provided, and the above-mentioned effect is easily achieved.
【0008】上記母液は輸液、透析液、臓器保存液に用
いられる成分であり、例えば、ナトリウム、カリウム、
マグネシウム、カルシウム、クロール、リン等、その他
の人体に存在する無機電解質、酢酸、乳酸、クエン酸
等、その他の人体に存在する有機電解質等であり、ま
た、電解質の他に糖類、アミノ酸、蛋白質、脂肪等のエ
ネルギー、必要により生理活性物質、ビタミン等も含ま
れる。尚、母液は樹脂容器に無菌的に充填しても良い
が、樹脂容器の収容室に液密収容した後、蒸気滅菌処理
されたものである。かかる滅菌処理により、母液の滅菌
が確実になされ、患者への安全な投与ができるからであ
る。上記炭酸成分とは重炭酸及び炭酸の一方又は両方を
いい、重炭酸のみ、炭酸のみでも良い。また炭酸成分は
重炭酸塩又は炭酸塩の固形塩で存在していても良いし、
かかるアルカリ塩溶液として存在しても良い。炭酸成分
に含まれる塩としては、アルカリ金属塩、アルカリ土類
金属塩等であり、特にナトリウム塩、カリウム塩である
ことが望ましい。また、炭酸成分には水酸化アルカリ塩
が含まれることが望ましい。例えば、水酸化ナトリウム
や水酸化カリウム等である。このように炭酸成分にアル
カリ塩が過剰に配合されていれば、炭酸ガス分解を極力
抑えることができる。[0008] The mother liquor is a component used for infusion, dialysate and organ preservation solution.
Magnesium, calcium, chlor, phosphorus, etc., other inorganic electrolytes present in the human body, acetic acid, lactic acid, citric acid, etc., and other organic electrolytes present in the human body, and, in addition to electrolytes, saccharides, amino acids, proteins, Energy such as fat and, if necessary, physiologically active substances and vitamins are also included. The mother liquor may be filled in the resin container aseptically, but is subjected to steam sterilization after being housed in a liquid-tight manner in the storage chamber of the resin container. This is because such a sterilization process ensures that the mother liquor is sterilized and can be safely administered to a patient. The carbonic acid component refers to one or both of bicarbonate and carbonic acid, and may be only bicarbonate or only carbonic acid. Further, the carbonic acid component may be present as a solid salt of bicarbonate or carbonate,
Such an alkali salt solution may be present. The salt contained in the carbonic acid component is an alkali metal salt, an alkaline earth metal salt, or the like, and particularly preferably a sodium salt or a potassium salt. Further, it is desirable that the carbonate component contains an alkali hydroxide salt. For example, sodium hydroxide or potassium hydroxide. As described above, if an excessive amount of the alkali salt is mixed in the carbonic acid component, the decomposition of carbon dioxide gas can be suppressed as much as possible.
【0009】上記炭酸成分は、少なくとも高圧蒸気滅菌
中或いは2〜3年の長期保存中に20%を限度として重
炭酸塩が炭酸ガスに分解消失しない状態で上記室に収容
してあることが望ましい。上記炭酸成分中から炭酸ガス
を放出しない方法としては、上記樹脂容器壁をガスバリ
アー性層で形成、或いは少なくとも樹脂容器の炭酸成分
を収容した室をガスバリアー性包装体で密封することが
望ましい。樹脂容器における蒸気滅菌処理は温度100
℃〜140℃、特に温度105℃〜115℃の範囲で滅
菌処理することが望ましい。上記範囲を下回る滅菌温度
では、時間がかかり、また滅菌が不十分となるおそれが
ある。一方、上記範囲を上回る滅菌温度ではプラスチッ
ク容器や包装材が熱変形、熱変質等を起こして好ましく
ない。The above-mentioned carbonic acid component is desirably housed in the above-mentioned chamber in a state where the bicarbonate is not decomposed into carbon dioxide gas at a maximum of 20% during high-pressure steam sterilization or long-term storage for 2-3 years. . As a method of not releasing carbon dioxide gas from the carbonic acid component, it is desirable to form the resin container wall with a gas barrier layer or to seal at least the chamber containing the carbonic acid component of the resin container with a gas barrier package. Steam sterilization in a resin container is performed at a temperature of 100.
It is desirable to carry out sterilization at a temperature in the range of from 140C to 140C, especially from 105C to 115C. At a sterilization temperature below the above range, it takes time and sterilization may be insufficient. On the other hand, if the sterilization temperature exceeds the above range, the plastic container and the packaging material are undesirably subjected to thermal deformation, thermal deterioration and the like.
【0010】このように構成した医療用容器の製造方法
では、蒸気滅菌中に炭酸成分がアルカリ性状態で存在す
るため、加熱中であっても炭酸ガスの発生が極力抑えら
れる。特に、固形状態に比べて分解し易い溶液状態の炭
酸成分でも加熱分解が抑えられる。従って、炭酸成分の
蒸気滅菌処理も可能となり、患者への安全な投与ができ
る。また、滅菌冷却後にも炭酸成分をアルカリ性状態に
維持可能なので、長期保存中にも炭酸ガスの発生を極力
抑えることができる。In the method for manufacturing a medical container constructed as described above, the carbonic acid component is present in an alkaline state during steam sterilization, so that the generation of carbon dioxide gas is suppressed as much as possible even during heating. In particular, thermal decomposition can be suppressed even with a carbonate component in a solution state that is more easily decomposed than a solid state. Therefore, steam sterilization of the carbonic acid component is also possible, and safe administration to a patient can be achieved. In addition, since the carbonic acid component can be maintained in an alkaline state even after sterilization and cooling, generation of carbon dioxide gas can be suppressed as much as possible during long-term storage.
【0011】本発明に係る請求項2記載の医療用容器の
製造方法は、請求項1記載の製造方法において、上記母
液中の[OH-]を除く負電解質量は母液中の[H+]を
除く陽電解質量より1.5mEq/L〜14mEq/L
の範囲(但し、上記炭酸成分中に重炭酸量より過剰な陽
電解質量(塩)が存在する場合には該陽電解質の過剰量
の負電解質を加算した後の範囲)で過剰に含めることを
特徴とする。母液は電解質溶液であるため通常、溶液中
には{OH-、X-、Y-、Z-、・・・}と{H+、A+、
B+、C+・・}との種々の陽及び負イオンが解離して存
在している。そして、PH値が7付近であれば、水素イ
オン及び水酸基イオンを除いた場合でも{X-、Y-、Z
-・・}と{A+、B+、C+・・}との陽・負電解質イオ
ン量は等しい。しかし、負電解質を陽電解質より過剰に
存在させた場合、過剰負電解質イオン量≒{X-、Y-、
Z-・・}−{A+、B+、C+・・}となり、かかる負電
解質イオン量と溶液中の水素イオン[H+]とが平衡を
保ちPH値が下がる。ここで、過剰負電解質中に弱酸、
例えば乳酸や酢酸が存在すると、母液のPH値は乳酸或
いは酢酸の電離定数Kと過剰負電解質量Cとでほぼ決ま
る。即ち、乳酸或いは酢酸以外の塩素等は殆ど電離し、
電離し難い乳酸或いは酢酸によってPH値が決まり、P
H値はPH≒−1/2・logK・Cの式にほぼ従う。
従って、乳酸の電離定数がK=1.38×10-4で、過
剰負電解質量Cが1.5mEq/Lであれば、その溶液
はPH値は3.34となる。また、電離定数の極めて低
い酢酸が母液に含まれ、1.5mEq/Lが過剰負電解
質量であれば、酢酸の解離定数Kが1.85×10-5で
あり、母液のPH値は3.80となる。また、弱酸がな
く、強酸のみの場合、例えば塩酸のみの場合はその90
%程度が解離することから過剰負電解質量Cがそのまま
反映し、PH値は2.74程度となる。[0011] manufacturing method of a medical container according to claim 2, wherein according to the present invention is the manufacturing method according to claim 1, wherein the mother liquor [OH -] negative electrolyte content except the mother liquor [H +] 1.5 mEq / L to 14 mEq / L from the weight of the positive electrolyte excluding
(However, if the carbonic acid component contains an excess of positive electrolyte mass (salt) than the amount of bicarbonate in the carbonic acid component, the excess amount of the positive electrolyte must be added after adding the negative electrolyte). Features. Since the mother liquor is an electrolyte solution, the solution usually contains {OH − , X − , Y − , Z − ,...} And {H + , A + ,
Various positive and negative ions with B + , C + ··· are dissociated. If the PH value is around 7, ΔX − , Y − , Z can be obtained even when hydrogen ions and hydroxyl ions are excluded.
- · ·} and {A +, B +, positive and negative electrolyte ions of the C + ...} are equal. However, when the negative electrolyte is present in excess of the positive electrolyte, the excess negative electrolyte ion amount ΔX − , Y − ,
Z − ··· −−A + , B + , C + ··}, and the PH value decreases while maintaining the equilibrium between the amount of negative electrolyte ions and the hydrogen ions [H + ] in the solution. Here, weak acid in excess negative electrolyte,
For example, when lactic acid or acetic acid is present, the PH value of the mother liquor is substantially determined by the ionization constant K of lactic acid or acetic acid and the excess negative electrolytic mass C. That is, chlorine other than lactic acid or acetic acid is almost ionized,
The pH value is determined by lactic acid or acetic acid, which is difficult to ionize.
The H value approximately follows the equation of PH ≒ -1 / 2 · logK · C.
Therefore, if the ionization constant of lactic acid is K = 1.38 × 10 −4 and the excess negative electrolytic mass C is 1.5 mEq / L, the solution has a PH value of 3.34. Also, if acetic acid having an extremely low ionization constant is contained in the mother liquor and 1.5 mEq / L is an excess negative electrolytic mass, the dissociation constant K of acetic acid is 1.85 × 10 -5 and the PH value of the mother liquor is 3 .80. In the case where there is no weak acid and only strong acid, for example, in the case of only hydrochloric acid, 90%
% Is dissociated, the excess negative electrolytic mass C is directly reflected, and the PH value is about 2.74.
【0012】このような[OH-]と[H+]を除く、負
電解質量が陽電解質量より過剰に存在する母液にあって
は、例えば25.5mmol/Lに相当する重炭酸ナト
リウムからなる炭酸成分を負電解質過剰量1.5mEq
/Lの母液に混合すると、炭酸成分は更に乳酸よりも弱
酸であるため、炭酸成分と結合していた25.5mmo
l中のナトリウムイオンが1.5mEq/L分だけ酢酸
或いは乳酸の負電解質と電離関係を持つ。ここで、その
他の電解質の緩衝作用により混合液のPH値が7付近に
維持されると、水酸基イオンも水素イオンもナノ単位量
であるため、25.5mEq/L中1.5mmolの
[HCO3 -]は[H+]と結合して炭酸ガスを生じる。
生成炭酸ガスの一部は混合液中に溶解或いは電離状態で
存在し、その他は溶解度等の関係により溶液外に炭酸ガ
スとして放出する。一方、重炭酸イオン及び炭酸イオン
のイオン総和量は24.0mEq/Lが確実に溶液中に
維持される。Except for [OH − ] and [H + ], the mother liquor in which the negative electrolytic mass is in excess of the positive electrolytic mass consists of, for example, sodium bicarbonate equivalent to 25.5 mmol / L. The carbonic acid component is converted to a negative electrolyte excess of 1.5 mEq.
/ L of the mother liquor, the carbonic acid component is weaker than lactic acid.
The sodium ion in 1 has an ionizing relationship with the negative electrolyte of acetic acid or lactic acid by 1.5 mEq / L. Here, when the pH value of the mixed solution is maintained at around 7 due to the buffering action of the other electrolytes, both the hydroxyl ions and the hydrogen ions are in a nano unit amount, so that 1.5 mmol [HCO 3 in 25.5 mEq / L]. - ] Combines with [H + ] to generate carbon dioxide gas.
Some of the generated carbon dioxide gas is dissolved or ionized in the mixed solution, and the other is released as carbon dioxide gas out of the solution due to solubility and the like. On the other hand, the total amount of bicarbonate ions and carbonate ions is maintained at 24.0 mEq / L in the solution.
【0013】本発明に係る医療用容器の製造方法は、母
液がかかる過剰負電解質を有することにより、母液と炭
酸成分とを混合した溶液のPH値をほぼ一定にし、且つ
体内の血漿等と同様に所定の重炭酸イオンと炭酸ガスと
を含む輸液剤等の医療用容器を提供できるようにしたも
のである。即ち、炭酸成分は、蒸気滅菌時或いは保存時
に予め、最低で5±3%、最高で20±3%程度まで炭
酸ガスとして消失してしまうことが通常見込まれる。ま
た、炭酸成分は輸液剤或いは透析液等の医療用溶液に1
0〜35mEq/L、特に20〜28mEq/Lの重炭
酸イオン濃度となるように最終的に含まれることが望ま
しい。このため、三年以上の保存にあっては、最下限の
10mEq/Lのときは誤差値の最低2%の消失が見込
まれ、最上限の35mEq/Lのときは誤差値の最高2
3%の消失が見込まれる。従って、0.2(10×0.
02)〜8.1(35×0.23)mEq/L量の範囲
で保存期間中の喪失が見込まれる。The method for producing a medical container according to the present invention is characterized in that the mother liquor has such an excess negative electrolyte so that the PH value of a solution obtained by mixing the mother liquor and a carbonate component is substantially constant, and the same as that of plasma in the body. And a medical container such as an infusion solution containing predetermined bicarbonate ions and carbon dioxide gas. That is, it is generally expected that the carbonic acid component will be eliminated as a carbon dioxide gas at a minimum of about 5 ± 3% and a maximum of about 20 ± 3% during steam sterilization or storage. The carbonic acid component is added to a medical solution such as an infusion solution or a dialysate.
It is desirable that the bicarbonate ion is finally contained so as to have a bicarbonate ion concentration of 0 to 35 mEq / L, particularly 20 to 28 mEq / L. Therefore, in storage for three years or more, at the lower limit of 10 mEq / L, a loss of at least 2% of the error value is expected, and at the upper limit of 35 mEq / L, the error value of the maximum is 2%.
3% disappearance is expected. Therefore, 0.2 (10 × 0.
02) to 8.1 (35 × 0.23) mEq / L, loss during the storage period is expected.
【0014】ところで、本発明に係る母液と炭酸成分と
を混合したとき、最初或いは保存中等のどの段階の混合
でも、母液中の過剰負電解質の作用により上記炭酸成分
の一部が混合時に常に反応発生し、医療用溶液のPH値
がほぼ所定範囲を維持し、また重炭酸イオン濃度を一定
にすることができる。例えば、疑似血漿に近い電解質成
分において、母液中の上記過剰負電解質量が4mEq/
L過剰で、重炭酸ナトリウムが分割室内に当初27mm
ol/L相当量あるとする。かかる母液と炭酸成分とを
高圧蒸気滅菌処理することなく混合すると、その混合し
た混合溶液から4mEq/L相当の重炭酸イオンが炭酸
ガスとして変化し、その炭酸ガスは一部は医療用溶液中
にあって溶解或いは電離し、一部は溶液外に放出され
る。即ち、過剰負電解質は重炭酸イオン27mmol/
L中の4mmol/Lの重炭酸イオンから陽イオン塩を
奪って電離関係を持つ。そして、混合溶液中の重炭酸イ
オン濃度はほぼ23mEq/L(厳密には、PH値7付
近で、[HCO3 -]≒[HCO3 -]+[CO3 2-]+
[OH-]=23mEq/L)となる。また、このとき
のPH値が下記化1のヘンダーソン・ハッセルバルヒの
式にほぼ従うとすると、そのPH値は医療用溶液中の炭
酸ガス濃度に左右され、混合溶液中に発生した炭酸ガス
4mmol(4/0.03[mmHg])の内、実験等
から40%程度が溶液外に放出されるので、医療用溶液
のPH値は7.10程度となる。By the way, when the mother liquor according to the present invention is mixed with a carbonic acid component, at any stage of mixing, initially or during storage, part of the carbonic acid component always reacts during mixing due to the action of the excess negative electrolyte in the mother liquor. Occurs, the PH value of the medical solution can be maintained in a substantially predetermined range, and the bicarbonate ion concentration can be kept constant. For example, in the electrolyte component close to the simulated plasma, the excess negative electrolytic mass in the mother liquor is 4 mEq /
L excess, sodium bicarbonate initially 27 mm
ol / L. When the mother liquor and the carbonic acid component are mixed without being subjected to high-pressure steam sterilization, bicarbonate ions equivalent to 4 mEq / L are changed as carbon dioxide gas from the mixed solution, and the carbon dioxide gas is partially contained in the medical solution. It is dissolved or ionized, and a part is released out of the solution. That is, the excess negative electrolyte is 27 mmol / bicarbonate ion.
The cation salt is deprived of 4 mmol / L bicarbonate ion in L and has an ionization relationship. The bicarbonate ion concentration in the mixed solution is approximately 23 mEq / L (strictly speaking, when the pH value is around 7, [HCO 3 − ] ≒ [HCO 3 − ] + [CO 3 2− ] +
[OH -] = 23mEq / L ) to become. Assuming that the PH value at this time substantially follows the Henderson-Hasselbarch equation of the following chemical formula 1, the PH value depends on the concentration of carbon dioxide in the medical solution, and 4 mmol (4%) of carbon dioxide generated in the mixed solution. /0.03 [mmHg]), about 40% is released out of the solution from experiments and the like, so that the PH value of the medical solution is about 7.10.
【0015】[0015]
【化1】 Embedded image
【0016】また、炭酸成分を容器と共に室内で蒸気滅
菌処理したときに加熱により分解消失して、重炭酸塩が
25mmol/L相当量にまで減少し、2mmol/L
相当量の水酸化塩等ができたとしても、混合する医療用
溶液からは、2mEq/Lに相当する重炭酸が炭酸ガス
となる。即ち、過剰負電解質の内の2mEq/Lが水酸
化塩と電離関係を持ち、残りの2mEq/Lは重炭酸イ
オンから奪った陽イオン塩と電離関係を持つ。生成炭酸
ガス中の30%程度が実験等から溶液外に放出されると
すると、その医療用溶液のPH値は7.31程度で重炭
酸イオン濃度は上記と同様にほぼ23mEq/Lとな
る。Further, when the carbonic acid component is steam-sterilized in a room together with the container, the carbonic acid component is decomposed and disappeared by heating, and the bicarbonate is reduced to an amount equivalent to 25 mmol / L, and 2 mmol / L.
Even if a considerable amount of hydroxide or the like is formed, bicarbonate equivalent to 2 mEq / L is converted into carbon dioxide gas from the mixed medical solution. That is, 2 mEq / L of the excess negative electrolyte has an ionization relationship with the hydroxide salt, and the remaining 2 mEq / L has an ionization relationship with the cation salt deprived of the bicarbonate ion. Assuming that about 30% of the generated carbon dioxide gas is released out of the solution from an experiment or the like, the PH value of the medical solution is about 7.31, and the bicarbonate ion concentration is approximately 23 mEq / L as described above.
【0017】上記母液中には[OH-]を除くこのよう
な負電解質量が母液中の[H+]を除く陽電解質量より
1.5mEq/L〜14mEq/Lの範囲で過剰に含ま
れる。 輸液剤等の医療用溶液中には炭酸ガスの溶存量
として少なくとも炭酸ガス分圧が40mmHgの付近に
あることが望ましい。このため、輸液溶液として溶液中
に1.2(40×0.03)mEq/L以上の炭酸ガス
が混合時に生成溶解することが望ましい。上記炭酸成分
の保存時の分解消失量は0.2〜8.1mmol/Lの
範囲が考えられることから、母液中の過剰負電解質量の
下限値が分解量を含めて1.4mEq/Lで上記下限範
囲はかかる下限値を上回る範囲の1.5mEq/Lに設
定されるべきである。一方、母液中の過剰負電解質量に
より分解した炭酸ガス分圧は200mmHgを限度とす
る。このため、輸液溶液として溶液中に最大で6.0
(200×0.03)mEq/Lを下回る炭酸ガスの溶
解であればよい。従って、母液中の過剰負電解質量の上
限値は保存中の分解量を含めて14.1mEq/Lで上
記上限範囲はかかる上限値を下回る範囲の14.0mE
q/Lに設定すべきである。このような過剰負電解質を
有する母液はPH値が3.80以下、特にPH値が3.
20以下、更にはPH値が2.90以下であることが望
ましい。尚、母液のPH値の下限は、炭酸成分に重炭酸
量を上回るアルカリ塩を含めることができるため制限す
る必要はない。即ち、上記母液中の過剰負電解質量の範
囲は、炭酸成分中に重炭酸イオン量より過剰な陽電解質
量(塩)が存在する場合には更に陽電解質量の過剰分の
負電解質を加算した範囲とすることができる。例えば、
上記例で言えば、炭酸成分中に重炭酸ナトリウム27m
mol/L相当量以外に水酸化ナトリウム27mmol
/L相当量が含まれていれば、母液中には27mEq/
L相当量の過剰の負電解質が上記過剰負電解質量の範囲
1.5〜14.0mEq/L相当量の範囲に更に加算さ
れる。従って、このような配合の母液を炭酸成分と分け
て充填した医療用容器の製造方法では使用の初期或いは
長期間の保存後の使用においてもPH値がほぼ所定の範
囲となるように用いることができ、その上、重炭酸イオ
ン量も一定に維持させることができる。また、母液中に
は糖類を添加する場合があるが、母液のPH値は3.8
以下であるため、母液の高圧蒸気滅菌中に糖類等が変
色、変質するおそれがない。[0017] The above mother liquor - contained in excess in such a [H +] range from positive electrolyte mass 1.5mEq / L~14mEq / L, except for the negative electrolyte mass mother liquor except [OH] . In a medical solution such as an infusion solution, it is desirable that the dissolved carbon dioxide gas has a carbon dioxide partial pressure of at least around 40 mmHg. For this reason, it is desirable that carbon dioxide gas of 1.2 (40 × 0.03) mEq / L or more is generated and dissolved in the infusion solution during mixing. Since the amount of decomposition and disappearance of the carbonate component during storage may range from 0.2 to 8.1 mmol / L, the lower limit of the excess negative electrolytic mass in the mother liquor is 1.4 mEq / L including the decomposition amount. The lower limit should be set to 1.5 mEq / L, which is higher than the lower limit. On the other hand, the partial pressure of carbon dioxide gas decomposed by the excess negative electrolytic mass in the mother liquor is limited to 200 mmHg. For this reason, as an infusion solution, a maximum of 6.0 in the solution.
Any dissolution of carbon dioxide gas below (200 × 0.03) mEq / L may be used. Therefore, the upper limit of the excess negative electrolytic mass in the mother liquor is 14.1 mEq / L including the amount of decomposition during storage, and the upper limit is 14.0 mE, which is lower than the upper limit.
It should be set to q / L. The mother liquor having such an excess negative electrolyte has a PH value of 3.80 or less, particularly a PH value of 3.80.
It is desirable that the PH value be 20 or less, and more preferably the PH value be 2.90 or less. The lower limit of the PH value of the mother liquor does not need to be limited because the carbonate component can contain an alkali salt exceeding the amount of bicarbonate. That is, the range of the excess negative electrolytic mass in the mother liquor is obtained by adding an excess of the negative electrolyte in the excess of the positive electrolytic mass when a positive electrolytic mass (salt) is present in the carbonate component in excess of the bicarbonate ion amount. Range. For example,
In the above example, 27m of sodium bicarbonate
mol / L equivalent to 27 mmol of sodium hydroxide
/ L equivalent amount, the mother liquor contains 27 mEq /
The excess amount of the negative electrolyte corresponding to L is further added to the above range of the excess negative electrolyte mass of 1.5 to 14.0 mEq / L. Therefore, in the method of manufacturing a medical container in which the mother liquor having such a composition is filled separately from the carbonic acid component, it is necessary to use the mother liquor so that the PH value is almost in a predetermined range even at the beginning of use or after use for a long period of time. In addition, the amount of bicarbonate ions can be kept constant. In addition, saccharides may be added to the mother liquor, but the pH value of the mother liquor is 3.8.
Because of the following, there is no possibility that saccharides or the like will be discolored or deteriorated during high-pressure steam sterilization of the mother liquor.
【0018】本発明に係る請求項3記載の医療用容器は
請求項2記載の医療用容器において、上記炭酸成分がア
ルカリ性懸濁液又は溶液として収容し、上記母液中の負
電解質量は母液中の[H+]を除く陽電解質量より3.
1mEq/L〜14mEq/Lの範囲(但し、上記炭酸
成分中に重炭酸量より過剰な陽電解質量(塩)が存在す
る場合には該陽電解質の過剰量の負電解質を加算した後
の範囲)で過剰に含めることを特徴とする。上記炭酸成
分をアルカリ性の懸濁液或いは溶液とした場合、通常、
固形塩より分解が速くなり、特に、熱等が加わったとき
には、過酷試験等の保存期間中に全体の20%程度が分
解する。このため、上記炭酸成分の分解消失量の範囲は
1.7〜8.1mEq/Lとなり、使用時の母液と炭酸
成分との混合時の炭酸ガスの好ましい溶存量を加算する
と、上記母液中の負電解質量は3.1mEq/L以上で
あることが望ましい。According to a third aspect of the present invention, there is provided the medical container according to the second aspect, wherein the carbonate component is contained as an alkaline suspension or solution, and the negative electrolytic mass in the mother liquor is the same as that in the mother liquor. 2. From the positive electrolytic mass excluding [H + ]
In the range of 1 mEq / L to 14 mEq / L (however, when the carbonic acid component contains a positive electrolytic mass (salt) in excess of the bicarbonate amount, the range after adding an excessive amount of the negative electrolyte to the positive electrolyte is added. ) Is included in excess. When the carbonic acid component is an alkaline suspension or solution,
Decomposition is faster than solid salts, and particularly when heat or the like is applied, about 20% of the whole decomposes during a storage period such as a severe test. For this reason, the range of the amount of decomposition and disappearance of the carbonic acid component is 1.7 to 8.1 mEq / L, and when the preferable dissolved amount of the carbon dioxide gas when the mother liquor is mixed with the carbonic acid component at the time of use is added, The negative electrolytic mass is desirably not less than 3.1 mEq / L.
【0019】本発明に係る請求項4記載の医療用容器の
製造方法は、請求項2又は3記載の製造方法において、
上記炭酸成分と母液との混合後の医療用溶液の炭酸ガス
濃度が10〜200mHgで存在することを特徴とす
る。上記母液と炭酸成分とを混合したとき、上述したよ
うに母液中の過剰負電解質が炭酸成分中の塩の一部と電
離関係を生じることにより、炭酸成分の一部は炭酸ガス
となるが、かかる炭酸ガスは混合後の混合溶液中に濃度
10〜200mHgの範囲、特に、20〜80mHgの
範囲の濃度となることが望ましい。上記混合溶液中の炭
酸ガス濃度は、上記ヘンダーソン・ハッセルバルヒの式
の溶液のPH値とPH7付近での理論的に存在する重炭
酸イオン量とに基づいて計算される値である。混合溶液
である医療用溶液が上記範囲を下回ると、血漿中等に一
過性の呼吸性アルカリローシスを引き起こし、体内での
炭酸ガス濃度の平衡バランスを崩すおそれがある。上記
範囲を上回ると、一過性の呼吸性アシドーシスとなり肺
からの代謝を上回り十分に平衡バランスを採ることがで
きなくなる。According to a fourth aspect of the present invention, there is provided a method of manufacturing a medical container, comprising the steps of:
The medical solution after mixing the carbonic acid component and the mother liquor has a carbon dioxide gas concentration of 10 to 200 mHg. When the mother liquor and the carbonic acid component are mixed, the excess negative electrolyte in the mother liquor causes an ionization relationship with a part of the salt in the carbonic acid component as described above, so that a part of the carbonic acid component becomes carbon dioxide gas. It is desirable that the concentration of the carbon dioxide gas in the mixed solution after mixing is in the range of 10 to 200 mHg, particularly 20 to 80 mHg. The carbon dioxide gas concentration in the mixed solution is a value calculated based on the PH value of the solution of the above-mentioned Henderson-Hasselbarch equation and the amount of bicarbonate ions present theoretically near PH7. If the medical solution as a mixed solution is below the above range, a transient respiratory alkali losis may be caused in plasma or the like, and the equilibrium balance of carbon dioxide concentration in the body may be lost. Above the above range, transient respiratory acidosis occurs, exceeding the metabolism from the lungs, and a sufficient balance cannot be achieved.
【0020】本発明に係る請求項5記載の医療用容器の
製造方法は、請求項2又は3記載の製造方法において、
上記炭酸成分の収容室を上記蒸気滅菌前又は滅菌後にガ
スバリアー性包装体で覆うことを特徴とする。上記炭酸
成分の収容室を蒸気滅菌前に覆うと、蒸気滅菌時の加温
中において炭酸ガスが包装体内に閉じ込められ炭酸成分
の分解を極力抑えることができる。また蒸気滅菌後にあ
っては保存中から使用直前までの炭酸成分の分解を極力
抑えることができる。本発明に係る包装体は、容器の全
体又は容器の一部の炭酸成分の収容室のみを密封包装す
るものである。具体的なガスバリアー性包装体として
は、包装壁が殆ど、又は全くガスを透過させないアルミ
ニウム等の金属層、またポリ塩化ビニリデン、ポリエス
テル、ナイロン、エチレン−ビニルアルコール共重合
体、フッ素系樹脂等のようにガスバリアー性の高い樹脂
層、又はアルミニウム、珪素、マグネシウム、チタン、
銀、金等の土類金属若しくは金属、又はその酸化物の蒸
着層等を有するものである。包装体におけるガスバリア
ー性層の酸素透過量は40cc・20μ/m2・day
・atm(温度:20℃)以下、特に、30cc・20
μ/m2・day・atm以下、また好ましくは5cc
・20μ/m2・day・atm以下、更には1cc・
20μ/m2・day・atm以下であることが望まし
い。包装体におけるガスバリアー性層の炭酸ガス透過量
は、200cc・20μ/m2・day・atm(温
度:25℃)以下、特に、100cc・20μ/m2・
day・atm以下、また好ましくは10cc・20μ
/m2・day・atm以下、更には1cc・20μ/
m2・day・atm以下であることが望ましい。According to a fifth aspect of the present invention, there is provided a method for manufacturing a medical container, comprising the steps of:
The storage chamber for the carbonic acid component is covered with a gas barrier package before or after the steam sterilization. If the accommodation room for the carbonic acid component is covered before the steam sterilization, the carbon dioxide gas is confined in the package during the heating during the steam sterilization, and the decomposition of the carbonic acid component can be suppressed as much as possible. Also, after steam sterilization, the decomposition of carbonic acid components during storage and immediately before use can be suppressed as much as possible. The package according to the present invention is a package in which the entire container or only a part of the container for containing the carbonated component is hermetically sealed. As a specific gas barrier packaging, the packaging wall has little or no gas permeation, such as a metal layer such as aluminum, polyvinylidene chloride, polyester, nylon, ethylene-vinyl alcohol copolymer, and a fluororesin. As a resin layer with high gas barrier properties, or aluminum, silicon, magnesium, titanium,
It has an earth metal such as silver, gold or the like, or a vapor-deposited layer of a metal or an oxide thereof. The oxygen permeation amount of the gas barrier layer in the package is 40 cc · 20 μ / m 2 · day
・ Atm (temperature: 20 ° C.) or less, especially 30 cc ・ 20
μ / m 2 · day · atm or less, preferably 5 cc
・ 20μ / m 2・ day ・ atm or less, 1cc ・
It is desirable to be 20 μ / m 2 · day · atm or less. The amount of carbon dioxide gas permeated by the gas barrier layer in the package is 200 cc · 20 μ / m 2 · day · atm (temperature: 25 ° C.) or less, particularly 100 cc · 20 μ / m 2 ·.
day · atm or less, preferably 10 cc · 20μ
/ M 2 · day · atm or less, and 1 cc · 20μ /
Desirably, it is equal to or less than m 2 · day · atm.
【0021】本発明に係る請求項6記載の医療用容器の
製造方法は、請求項5記載の製造方法において、上記ガ
スバリアー性包装体内に炭酸ガス発生型脱酸素剤を配す
ることを特徴とする。上記包装体内に炭酸ガス発生型脱
酸素剤を配すれば、包装体のガスバリアー性と相まって
炭酸成分の蒸気滅菌中或いは保存中の分解を極力抑える
ことができる。脱酸素剤としては、アスコルビン酸、カ
テコール系化合物を主体とした有機系のもの、或いは鉄
等の金属及びハロゲン化金属からなる粉末状のものなど
がある。具体的には、商品名「エージレス」(三菱瓦斯
化学株式会社)やその他のメーカー等から市販されてい
るものである。脱酸素剤としては、酸素を吸収して炭酸
ガスを発生するものである。According to a sixth aspect of the present invention, in the method for manufacturing a medical container, a carbon dioxide-generating type oxygen absorber is disposed in the gas barrier package. I do. If a carbon dioxide-generating type oxygen scavenger is disposed in the package, decomposition of the carbonic acid component during steam sterilization or storage can be suppressed as much as possible in combination with the gas barrier property of the package. Examples of the oxygen scavenger include organic compounds mainly composed of ascorbic acid and catechol-based compounds, and powdery compounds composed of metals such as iron and metal halides. Specifically, it is commercially available from the trade name “Ageless” (Mitsubishi Gas Chemical Co., Ltd.) or other manufacturers. The oxygen absorber absorbs oxygen to generate carbon dioxide gas.
【0022】[0022]
【実施例】以下、本発明に係る炭酸成分入り医療用溶液
を収容した医療用容器の製造方法の好ましい実施例を添
付図面を参照しながら詳述する。図1は本発明に係る炭
酸成分入り医療用溶液を収容した医療用容器の製造方法
における第一実施例の医療用容器の正面図である。図2
は第一実施例の医療用容器の炭酸成分の収容室に包装材
を設けた正面図である。図3は第一実施例の医療用容器
の収容室に設けた包装材の断面図である。DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS A preferred embodiment of the method for producing a medical container containing a carbonated medical solution according to the present invention will be described below in detail with reference to the accompanying drawings. FIG. 1 is a front view of the medical container of the first embodiment in the method for producing a medical container containing a carbonated medical solution according to the present invention. FIG.
FIG. 3 is a front view of a medical container according to the first embodiment, in which a packaging material is provided in a storage compartment for a carbonated component. FIG. 3 is a sectional view of the packaging material provided in the accommodation room of the medical container of the first embodiment.
【0023】本実施例に係る炭酸成分入り医療用溶液を
収容した医療用容器2の製造方法は、図1及び図2に示
す如く一の室5に重炭酸又は炭酸の塩の懸濁液から成る
炭酸成分6を液密に収容し、他の室4に炭酸成分6以外
の電解質からなる母液7を液密に収容したの後、上記炭
酸成分6及び母液7を分けた状態で蒸気滅菌処理し、該
滅菌処理後に上記炭酸成分6と母液7を混ぜてなる。ま
た本実施例に係る医療用容器2の製造方法は、上記母液
7中のPHを3.8以下とし、且つ上記母液7中の[O
H-]を除く負電解質量は母液7中の[H+]を除く陽電
解質量より1.5mEq/L〜10mEq/Lの範囲
(但し、上記炭酸成分6中に重炭酸量より過剰な陽電解
質量(塩)が存在する場合には該陽電解質の過剰量の負
電解質を加算した後の範囲)で過剰に含める。また本実
施例に係る医療用容器2の製造方法は、上記炭酸成分6
と母液7との混合後の混合溶液1の炭酸ガス濃度が10
〜200mHgで存在する。更に、上記炭酸成分6の収
容室5を上記蒸気滅菌前にガスバリアー性包装体11で
覆うと共に、上記ガスバリアー性包装体11内に炭酸ガ
ス発生型脱酸素剤16を配するものである。The method of manufacturing the medical container 2 containing the carbonated medical solution according to the present embodiment is as follows. As shown in FIGS. 1 and 2, a bicarbonate or carbonate salt suspension is placed in one chamber 5. After the carbonic acid component 6 is housed in a liquid-tight manner, the mother liquor 7 made of an electrolyte other than the carbonic acid component 6 is housed in another chamber 4 in a liquid-tight manner, and then the carbonic acid component 6 and the mother liquor 7 are separated and steam sterilized. After the sterilization treatment, the carbonate component 6 and the mother liquor 7 are mixed. In the method for manufacturing the medical container 2 according to the present embodiment, the pH of the mother liquor 7 is set to 3.8 or less, and the [O]
The negative electrolytic mass excluding H − ] is in the range of 1.5 mEq / L to 10 mEq / L from the positive electrolytic mass excluding [H + ] in the mother liquor 7 (provided that the excess amount of bicarbonate in the carbonic acid component 6 is larger than the amount of bicarbonate). If the electrolyte mass (salt) is present, it is included in excess (in the range after adding the excess amount of the negative electrolyte to the negative electrolyte). Further, the method for manufacturing the medical container 2 according to the present embodiment includes the above-described carbonic acid component 6.
Of the mixed solution 1 after the mixing of the
Present at ~ 200 mHg. Further, the accommodation room 5 for the carbonic acid component 6 is covered with a gas barrier package 11 before the steam sterilization, and a carbon dioxide-generating type oxygen absorber 16 is arranged in the gas barrier package 11.
【0024】第一実施例に係る炭酸成分入り医療用溶液
を収容した医療用容器2の製造方法を更に詳しく説明す
ると、先ず、インフレーション成形した透明で柔軟な可
撓性樹脂シートを所定の大きさに裁断する。樹脂シート
は肉厚が250μmで、内層が厚み50μmの直鎖状低
密度ポリエチレンとポリプロピレンとのブレンド物で、
外層が厚み200μmの低密度ポリエチレンの二層構造
からなる。直鎖状低密ポリエチレンは融点が126℃
で、ポリプロピレンは融点が160℃である。また、内
層は直鎖状低密度ポリエチレンとポリプロピレンとを6
5:35の割合でブレンドしたものである。次に、裁断
シートの中間部に収容室4と収容室5とを分ける隔離シ
ール部3、3を形成する。隔離シール部3は温度140
℃で10秒間ヒートシールして形成される。隔離シール
部は剥離開封可能なシール部として形成され、収容室4
を0.2Kgf/cm2以上で圧迫した時に剥離開封す
る。樹脂シートの裁断端部2Aから炭酸成分6を充填
し、その裁断端部2Aを熱溶着シールして液密にシール
する。裁断端部2Aはシール温度170℃及び6秒間の
ヒートシールで完全固着シールされる。炭酸成分6はア
ルカリ性重炭酸ナトリウムの懸濁液(3ml)からな
り、表1にサンプル1〜5の含量(1L溶液とした場合
の相当濃度)が示される。The method for manufacturing the medical container 2 containing the carbonated medical solution according to the first embodiment will be described in more detail. First, a transparent and flexible flexible resin sheet formed by inflation molding is formed into a predetermined size. Cut into pieces. The resin sheet is a blend of linear low-density polyethylene and polypropylene with a thickness of 250 μm and an inner layer of 50 μm,
The outer layer has a two-layer structure of low-density polyethylene having a thickness of 200 μm. Linear low density polyethylene has a melting point of 126 ° C
The melting point of polypropylene is 160 ° C. The inner layer is made of linear low-density polyethylene and polypropylene.
Blend at a ratio of 5:35. Next, isolation seal portions 3 for separating the storage chamber 4 and the storage chamber 5 are formed in the middle of the cut sheet. The isolation seal part 3 has a temperature of 140
It is formed by heat sealing at 10 ° C. for 10 seconds. The isolation seal portion is formed as a peelable sealable seal portion.
Is peeled and opened when pressed at 0.2 kgf / cm 2 or more. The cut end 2A of the resin sheet is filled with the carbonic acid component 6 and the cut end 2A is heat-sealed and sealed in a liquid-tight manner. The cut end 2A is completely fixed and sealed by heat sealing at 170 ° C. for 6 seconds. Carbonic acid component 6 is composed of a suspension (3 ml) of alkaline sodium bicarbonate, and Table 1 shows the contents of Samples 1 to 5 (corresponding concentrations in the case of 1 L solution).
【0025】[0025]
【表1】 [Table 1]
【0026】裁断シートの他の端部2Bを上記端部2A
と同様に固着シールする。かかるシールの際に排出口1
01を取付ける。排出口101は樹脂製の筒状部材から
なる。次に排出口101から1Lの母液7を充填し、排
出口101をゴム栓で液密に閉止する。ゴム栓には点滴
用針が刺通されるようになっている。母液7は輸液剤の
維持溶液に近い成分の電解質及び糖類が溶解され、表2
にサンプル1〜5の含量が示される。The other end 2B of the cut sheet is connected to the end 2A.
Sealing is performed in the same manner as described above. The outlet 1
Install 01. The discharge port 101 is formed of a cylindrical member made of resin. Next, 1 L of the mother liquor 7 is filled from the outlet 101, and the outlet 101 is closed liquid-tight with a rubber stopper. A drip needle is pierced through the rubber stopper. In the mother liquor 7, electrolytes and saccharides close to the maintenance solution of the infusion solution are dissolved, and
Shows the contents of Samples 1 to 5.
【0027】[0027]
【表2】 [Table 2]
【0028】図2に示す如く2枚のガスバリアー性の表
シート12と裏シート13で上記医療用容器2の収容室
5を覆い、表シート12と裏シート13の互いの周縁を
気密に熱溶着シールする。図3に示す如く表シート12
は最内層21が厚み100μmの直鎖状低密度ポリエチ
レンであり、第1中間層22が厚み15μmの延伸ナイ
ロンであり、第2中間層23が厚み9μmのアルミニウ
ム層であり、外層24が厚み12μmのポリエチレンテ
レフタレート層からなる。一方、裏シート13は、最内
層31が厚み100μmの直鎖状低密度ポリエチレンで
あり、第1中間層32が厚み15μmのポリ塩化ビニリ
デン層であり、第2中間層33及び第3中間層34が延
伸ナイロン層であり、第4中間層35が厚み9μmのア
ルミニウム層であり、外層36が厚み12μmのポリエ
チレンテレフタレート層からなる。そして、第2中間層
33と第3中間層34との間には剥離面Cが形成され、
裏シート13は剥離面Cを境に、被剥離壁Dと剥離壁E
とに分かれている。剥離壁Eには非透明性の第4中間層
35(アルミニウム層)が存在し、被剥離壁Dにはガス
バリアー性の第1中間層32(塩化ビニリデン層)が存
在している。被剥離壁Dは第1中間層32を有すること
により、その酸素ガス透過性が1cc/m2・day・
atm以下で、内容物の確認ができる程度に透明性を有
している。従って、両シート12、13の最内層21、
31は熱溶着シール層となっており、温度130℃及び
ヒートシール時間20秒間の条件で両シート12、13
は周縁で互いに熱溶着シールされる。As shown in FIG. 2, the housing chamber 5 of the medical container 2 is covered with two gas-barrier front and back sheets 12 and 13, and the peripheral edges of the front and back sheets 12 and 13 are air-tightly sealed. Seal by welding. As shown in FIG.
The innermost layer 21 is a linear low-density polyethylene having a thickness of 100 μm, the first intermediate layer 22 is a stretched nylon having a thickness of 15 μm, the second intermediate layer 23 is an aluminum layer having a thickness of 9 μm, and the outer layer 24 has a thickness of 12 μm. Of a polyethylene terephthalate layer. On the other hand, in the back sheet 13, the innermost layer 31 is a linear low-density polyethylene having a thickness of 100 μm, the first intermediate layer 32 is a polyvinylidene chloride layer having a thickness of 15 μm, the second intermediate layer 33 and the third intermediate layer 34. Is a stretched nylon layer, the fourth intermediate layer 35 is a 9 μm-thick aluminum layer, and the outer layer 36 is a 12 μm-thick polyethylene terephthalate layer. Then, a release surface C is formed between the second intermediate layer 33 and the third intermediate layer 34,
The backing sheet 13 is separated from the peeled surface C by the peeled wall D and the peeled wall E.
And divided into The non-transparent fourth intermediate layer 35 (aluminum layer) is present on the peeling wall E, and the gas barrier first intermediate layer 32 (vinylidene chloride layer) is present on the wall D to be peeled. Since the peeled wall D has the first intermediate layer 32, its oxygen gas permeability is 1 cc / m 2 · day ·
Atm or less, it has transparency to the extent that the contents can be confirmed. Therefore, the innermost layer 21 of both sheets 12, 13
Reference numeral 31 denotes a heat-sealing seal layer, which is formed on both sheets 12, 13 at a temperature of 130 ° C. and a heat sealing time of 20 seconds.
Are heat sealed together at the periphery.
【0029】また周縁の熱溶着シール部14は一部が医
療用容器2を挟んで隔離シール部3、3の間に形成され
ている。かかる熱溶着シール部14は隔離シール部3の
剥離強度等の剥離機能に影響を与えない温度で形成され
ることになる。また、熱溶着シール部14の上部には吊
り孔15を形成し、吊り孔15は使用時にスタンド等の
フックが係止される。これにより、包装体1を形成す
る。尚、表及び裏シート12、13の周縁を完全にシー
ルする前に脱酸素包装体11内には脱酸素剤16が配せ
られ、脱酸素剤16は重炭酸塩を含む炭酸ガス発生型の
除酸素剤である。次に、これをそのまま1日放置したも
のと、その後、オートクレーブ滅菌処理(110℃)し
たものに分けてサンプルを作製した。次に、各サンプル
の評価を行うため、医療用容器の隔離シール部3を剥離
した後、各サンプルのPH値、重炭酸イオンの測定(日
本薬局法の定量測定)及びPH値に基づく炭酸ガス分圧
を測定した。その結果を表3及び表4に示した。A part of the heat-sealing seal portion 14 at the periphery is formed between the isolation seal portions 3 with the medical container 2 interposed therebetween. Such a heat-sealed seal portion 14 is formed at a temperature that does not affect the peeling function such as the peel strength of the isolation seal portion 3. In addition, a suspension hole 15 is formed in the upper portion of the heat-sealing seal portion 14, and a hook such as a stand is locked in the suspension hole 15 during use. Thereby, the package 1 is formed. Before completely sealing the peripheral edges of the front and back sheets 12 and 13, an oxygen absorber 16 is disposed in the oxygen-absorbing package 11, and the oxygen absorber 16 is a carbon dioxide-generating type containing bicarbonate. It is an oxygen scavenger. Next, a sample was prepared by dividing the sample into one that was left as it was for one day and one that was then subjected to an autoclave sterilization treatment (110 ° C.). Next, in order to evaluate each sample, after separating the seal portion 3 of the medical container, the PH value of each sample, measurement of bicarbonate ion (quantitative measurement according to the Japanese Pharmacopoeia method), and carbon dioxide gas based on the PH value The partial pressure was measured. The results are shown in Tables 3 and 4.
【0030】[0030]
【表3】 [Table 3]
【0031】[0031]
【表4】 [Table 4]
【0032】表3及び4の結果から炭酸成分6と母液7
とを分けて収容して蒸気滅菌処理すれば、各サンプルと
も滅菌後の混合液のPH値、及び重炭酸イオン量が一定
に得られることが分かる。また、炭酸ガス分圧において
は、サンプル4及び5においてはPH値が低く、7付近
を維持しないため、化1式に従うかは疑問であるが、サ
ンプル1〜3を見る限り、炭酸ガス分圧の滅菌前後の変
化量にはあまり差がなく、炭酸ガス分圧も滅菌後は20
0mmHg以下に収まることから医療用溶液として使用
が期待できる。また、サンプル2とサンプル5にあって
は、混合後の密閉容器内でのPH値及び重炭酸イオン濃
度を追跡した。その結果を表5及び表6に示した。この
結果、PH値の変化は密閉系で炭酸ガスの放出も少ない
ことが分かった。また、サンプル2においては、化1式
より混合液中の炭酸ガス濃度は初期混合値が92mmH
gで1日放置後が58mmHgとなる。これは体内が許
容する十分な吸収量であり、十分な安定性が見られる。From the results in Tables 3 and 4, the carbonate component 6 and the mother liquor 7
It can be seen that if the components are separately stored and subjected to the steam sterilization treatment, the PH value and the bicarbonate ion amount of the mixed solution after sterilization can be constantly obtained for each sample. Regarding the carbon dioxide partial pressure, since the PH value of Samples 4 and 5 is low and does not maintain around 7, it is doubtful that Formula 1 is obeyed. The amount of change before and after sterilization did not differ much, and the carbon dioxide partial pressure was 20% after sterilization.
Since it falls below 0 mmHg, it can be expected to be used as a medical solution. In Samples 2 and 5, the PH value and the bicarbonate ion concentration in the closed container after mixing were tracked. The results are shown in Tables 5 and 6. As a result, it was found that the change in the PH value was that the release of carbon dioxide gas was small in the closed system. In sample 2, the carbon dioxide concentration in the mixed solution was found to be 92 mmH at the initial mixing value according to the formula 1.
g and 58 mmHg after standing for 1 day. This is a sufficient amount of absorption that the body allows, and sufficient stability is seen.
【0033】[0033]
【表5】 [Table 5]
【0034】[0034]
【表6】 [Table 6]
【0035】また、本実施例では、炭酸成分6に炭酸ナ
トリウムを28mmol/L相当量を用い、このきの母
液7には、過剰負電解質(乳酸を含む。)を4.5mE
q/L、炭酸成分6でのアルカリ塩過剰量の調整剤とし
て塩酸を28mEq/Lを余分に加えた組成とした。こ
の結果、母液7のPH値が1.60であり、滅菌した混
合後の混合液のPH値及び重炭酸イオン量の値は、重炭
酸塩が23.5mEq/Lで、PH値が7.11となっ
た。In this embodiment, sodium carbonate is used in an amount equivalent to 28 mmol / L for the carbonic acid component 6, and the mother liquor 7 contains an excess negative electrolyte (including lactic acid) of 4.5 mE.
q / L, a composition in which hydrochloric acid (28 mEq / L) was additionally added as a regulator of an excess amount of an alkali salt in the carbonic acid component 6. As a result, the PH value of the mother liquor 7 was 1.60, and the pH value and the amount of bicarbonate ions of the mixed solution after sterilization were 23.5 mEq / L for bicarbonate and 7.70 for bicarbonate. It was 11.
【0036】次に、上記医療用容器2における炭酸成分
6をアルカリ性重炭酸ナトリウム液(3ml)とする。
重炭酸ナトリウム量は、表7のサンプル6、7に示す通
りである(1L溶液とした場合の相当濃度)。医療用容
器2における母液7を1L収容し、母液7の成分は表8
のサンプル6、7に示す通りである。上記医療用容器2
は高圧蒸気滅菌され、滅菌後、保存温度60℃の1カ
月、2カ月、4カ月、及び6カ月の重炭酸量及びPH値
を測定した。また、母液と重炭成分を混合したときの重
炭酸イオン量及びそのPH値を測定するとともに、炭酸
成分6を母液でなく1Lの溶液に希釈して、炭酸成分6
の残存総量を測定した。結果を表9に示した。Next, the carbonic acid component 6 in the medical container 2 is changed to an alkaline sodium bicarbonate solution (3 ml).
The amount of sodium bicarbonate is as shown in Samples 6 and 7 in Table 7 (corresponding concentration when a 1 L solution was used). 1 L of the mother liquor 7 in the medical container 2 is stored, and the components of the mother liquor 7 are shown in Table 8
As shown in Samples 6 and 7. The medical container 2
Was subjected to high-pressure steam sterilization, and after the sterilization, the bicarbonate amount and the PH value were measured at a storage temperature of 60 ° C. for 1 month, 2 months, 4 months, and 6 months. In addition, while measuring the amount of bicarbonate ions and the PH value thereof when the mother liquor and the heavy carbon component were mixed, the carbonic acid component 6 was diluted not to the mother liquor but to a 1-liter solution, and
Was measured. The results are shown in Table 9.
【0037】[0037]
【表7】 [Table 7]
【0038】[0038]
【表8】 [Table 8]
【0039】[0039]
【表9】 [Table 9]
【0040】この結果、過酷試験により室5内の炭酸成
分6は80%近くまで減少するが、炭酸成分6と母液7
を混合した場合の重炭酸イオン量には変化が見られず、
また、PH値及び炭酸ガス量も必要十分量に維持されて
いる。上記実施例では、輸液剤の組成を用いたが、臓器
保存液等に用いても良い。上記実施例では、輸液剤の母
液を一の収容室4に収容したが、アミノ酸と糖とを含む
ものについては収容室4を更に2以上の室に分けても良
い。上記実施例では、インフレーション樹脂シートから
容器本体を成形したが、可撓性で透明性を有する限り、
ブロー成形物、射出成形物、真空成形物等であっても良
い。上記実施例では、容器に室を分けて主配合剤と補助
配合剤とを区分したが、別別の容器を接続させて形成し
ても良く、また、無菌的連通手段は剥離可能な隔離シー
ル部である必要はない。As a result, the carbonic acid component 6 in the chamber 5 was reduced to nearly 80% by the severe test, but the carbonic acid component 6 and the mother liquor 7
No change was observed in the amount of bicarbonate ions when
Also, the PH value and the amount of carbon dioxide gas are maintained at necessary and sufficient amounts. In the above embodiment, the composition of the infusion solution was used, but the composition may be used for an organ preservation solution or the like. In the above embodiment, the mother liquor of the infusion solution is stored in one storage chamber 4, but the storage chamber 4 may be further divided into two or more chambers containing an amino acid and a sugar. In the above example, the container body was molded from the inflation resin sheet, but as long as it has flexibility and transparency,
It may be a blow molded product, an injection molded product, a vacuum molded product, or the like. In the above embodiment, the main compounding agent and the auxiliary compounding agent are separated by dividing the chamber into containers, but may be formed by connecting another container, and the aseptic communication means is a detachable isolation seal. It doesn't have to be a department.
【0041】[0041]
【発明の効果】以上説明したように本発明に係る炭酸成
分入り医療用溶液を収容した医療用容器の製造方法によ
れば、一の室に重炭酸又は炭酸の塩又は塩溶液から成る
炭酸成分を液密に収容し、他の室に重炭酸以外の電解質
からなる母液を液密に収容したの後、上記炭酸成分及び
母液を分けた状態で蒸気滅菌処理し、該滅菌処理後に上
記炭酸成分と母液を混ぜてなるので、製造前、製造後、
或いは長期保存後のどの段階であっても使用に際して、
医療用溶液はPH値がほぼ一定に維持され、且つ炭酸ガ
ス濃度も一定に維持される。As described above, according to the method for producing a medical container containing a medical solution containing a carbonic acid component according to the present invention, the carbonic acid component comprising a salt or a salt solution of bicarbonate or carbonic acid in one chamber. After the mother liquor containing an electrolyte other than bicarbonate is housed in another chamber in a liquid-tight manner, the carbonic acid component and the mother liquor are subjected to steam sterilization in a separated state. And mother liquor, so before and after production,
Or, at any stage after long-term storage,
The PH value of the medical solution is kept almost constant, and the concentration of carbon dioxide is also kept constant.
【図1】図1は本発明に係る炭酸成分入り医療用溶液を
収容した医療用容器の製造方法における第一実施例の医
療用容器の正面図である。FIG. 1 is a front view of a medical container of a first embodiment in a method for producing a medical container containing a carbonated medical solution according to the present invention.
【図2】図2は第一実施例の医療用容器の炭酸成分の収
容室に包装材を設けた正面図である。FIG. 2 is a front view of the medical container according to the first embodiment, in which a packaging material is provided in a carbonic acid component accommodating chamber.
【図3】図3は第一実施例の医療用容器の収容室に設け
た包装材の断面図である。FIG. 3 is a sectional view of a packaging material provided in a storage chamber of the medical container of the first embodiment.
1 薬液 2 医療用容器 3 隔離シール部 4 母液の収容室 5 炭酸成分の収容室 6 炭酸成分 7 母液 DESCRIPTION OF SYMBOLS 1 Chemical solution 2 Medical container 3 Isolation seal part 4 Mother liquid storage room 5 Carbonic acid component storage room 6 Carbonic acid component 7 Mother liquid
Claims (6)
ら成る炭酸成分を液密に収容し、他の室に炭酸成分以外
の電解質からなる母液を液密に収容したの後、上記炭酸
成分及び母液を分けた状態で蒸気滅菌処理し、該滅菌処
理後に上記炭酸成分と母液を混ぜてなる炭酸成分入り医
療用溶液を収容した医療用容器の製造方法。(1) A carbonic acid component comprising a salt or a salt solution of bicarbonate or carbonic acid is accommodated in one chamber in a liquid-tight manner, and a mother liquor comprising an electrolyte other than the carbonic acid ingredient is accommodated in another chamber in a liquid-tight manner. A method for producing a medical container containing a medical solution containing a carbonic acid component, which is subjected to steam sterilization in a state where the carbonic acid component and the mother liquor are separated, and after the sterilization treatment, the carbonic acid component and the mother liquor are mixed.
上記母液中の[OH-]を除く負電解質量は母液中の
[H+]を除く陽電解質量より1.5mEq/L〜14
mEq/Lの範囲(但し、上記炭酸成分中に重炭酸量よ
り過剰な陽電解質量(塩)が存在する場合には該陽電解
質の過剰量の負電解質を加算した後の範囲)で過剰に含
めることを特徴とする請求項1記載の医療用容器の製造
方法。2. The pH of the mother liquor is set to 3.8 or less, and the negative electrolytic mass excluding [OH − ] in the mother liquor is 1.5 mEq / L from the positive electrolytic mass excluding [H + ] in the mother liquor. ~ 14
In the range of mEq / L (however, in the case where the amount of the positive electrolyte (salt) in excess of the amount of bicarbonate is present in the above-mentioned carbonic acid component, the range is obtained after adding the excess amount of the negative electrolyte to the excess amount of the positive electrolyte). The method for producing a medical container according to claim 1, wherein:
として収容し、上記母液中の負電解質量は母液中の[H
+]を除く陽電解質量より3.1mEq/L〜14mE
q/Lの範囲(但し、上記炭酸成分中に重炭酸量より過
剰な陽電解質量(塩)が存在する場合には該陽電解質の
過剰量の負電解質を加算した後の範囲)で過剰に含める
ことを特徴とする請求項2記載の医療用容器の製造方
法。3. The method according to claim 1, wherein the carbonic acid component is contained as an alkaline suspension or solution, and the negative electrolytic mass in the mother liquor is [H] in the mother liquor.
+ ] From 3.1 mEq / L to 14 mE
In the range of q / L (however, when there is an excess of the positive electrolyte mass (salt) in the carbonic acid component in excess of the bicarbonate amount, the range after adding the negative electrolyte in an excess amount of the positive electrolyte) 3. The method for manufacturing a medical container according to claim 2, wherein the method includes:
液の炭酸ガス濃度が10〜200mHgで存在すること
を特徴とする請求項2又は3記載の医療用容器の製造方
法。4. The method for producing a medical container according to claim 2, wherein a carbon dioxide gas concentration of the medical solution after mixing the carbonic acid component and the mother liquor is in a range of 10 to 200 mHg.
は滅菌後にガスバリアー性包装体で覆うことを特徴とす
る請求項4記載の医療用容器の製造方法。5. The method for producing a medical container according to claim 4, wherein the accommodation room for the carbonic acid component is covered with a gas barrier package before or after the steam sterilization.
生型脱酸素剤を配することを特徴とする請求項5記載の
医療用容器の製造方法。6. The method for producing a medical container according to claim 5, wherein a carbon dioxide-generating type oxygen scavenger is disposed in the gas barrier package.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP33781297A JP3213271B2 (en) | 1997-05-08 | 1997-11-21 | Method for producing medical container containing medical solution containing carbonic acid component |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9-134259 | 1997-05-08 | ||
JP13425997 | 1997-05-08 | ||
JP33781297A JP3213271B2 (en) | 1997-05-08 | 1997-11-21 | Method for producing medical container containing medical solution containing carbonic acid component |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH1119178A true JPH1119178A (en) | 1999-01-26 |
JP3213271B2 JP3213271B2 (en) | 2001-10-02 |
Family
ID=26468397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP33781297A Expired - Fee Related JP3213271B2 (en) | 1997-05-08 | 1997-11-21 | Method for producing medical container containing medical solution containing carbonic acid component |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3213271B2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6309673B1 (en) | 1999-09-10 | 2001-10-30 | Baxter International Inc. | Bicarbonate-based solution in two parts for peritoneal dialysis or substitution in continuous renal replacement therapy |
JP2003081359A (en) * | 2001-09-11 | 2003-03-19 | Toyo Seikan Kaisha Ltd | Packaging bag for microwave oven and manufacturing method for packaging item having content filled in packaging bag |
US7011855B2 (en) | 1994-07-01 | 2006-03-14 | Baxter International Inc. | Biochemically balanced peritoneal dialysis solutions |
US7122210B2 (en) | 2002-01-11 | 2006-10-17 | Baxter International Inc. | Bicarbonate-based solutions for dialysis therapies |
JP2008201477A (en) * | 2006-12-12 | 2008-09-04 | Toyo Seikan Kaisha Ltd | Plastic pouch having detachable sealing part |
US7445801B2 (en) | 2002-06-07 | 2008-11-04 | Baxter International Inc. | Stable bicarbonate-based solution in a single container |
US8052631B2 (en) | 2005-01-28 | 2011-11-08 | Fresenius Medical Care Holdings, Inc. | Systems and methods for delivery of peritoneal dialysis (PD) solutions |
US9585810B2 (en) | 2010-10-14 | 2017-03-07 | Fresenius Medical Care Holdings, Inc. | Systems and methods for delivery of peritoneal dialysis (PD) solutions with integrated inter-chamber diffuser |
-
1997
- 1997-11-21 JP JP33781297A patent/JP3213271B2/en not_active Expired - Fee Related
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7011855B2 (en) | 1994-07-01 | 2006-03-14 | Baxter International Inc. | Biochemically balanced peritoneal dialysis solutions |
US6309673B1 (en) | 1999-09-10 | 2001-10-30 | Baxter International Inc. | Bicarbonate-based solution in two parts for peritoneal dialysis or substitution in continuous renal replacement therapy |
US6475529B2 (en) | 1999-09-10 | 2002-11-05 | Baxter International Inc. | Bicarbonate-based solution in two parts for peritoneal dialysis or substitution in continuous renal replacement therapy |
JP2003081359A (en) * | 2001-09-11 | 2003-03-19 | Toyo Seikan Kaisha Ltd | Packaging bag for microwave oven and manufacturing method for packaging item having content filled in packaging bag |
US7122210B2 (en) | 2002-01-11 | 2006-10-17 | Baxter International Inc. | Bicarbonate-based solutions for dialysis therapies |
US7445801B2 (en) | 2002-06-07 | 2008-11-04 | Baxter International Inc. | Stable bicarbonate-based solution in a single container |
US8052631B2 (en) | 2005-01-28 | 2011-11-08 | Fresenius Medical Care Holdings, Inc. | Systems and methods for delivery of peritoneal dialysis (PD) solutions |
US8328784B2 (en) | 2005-01-28 | 2012-12-11 | Fresenius Medical Care Holdings, Inc. | Systems and methods for delivery of peritoneal dialysis (PD) solutions |
US9180069B2 (en) | 2005-01-28 | 2015-11-10 | Fresenius Medical Care Holdings, Inc. | Systems and methods for delivery of peritoneal dialysis (PD) solutions |
JP2008201477A (en) * | 2006-12-12 | 2008-09-04 | Toyo Seikan Kaisha Ltd | Plastic pouch having detachable sealing part |
US9585810B2 (en) | 2010-10-14 | 2017-03-07 | Fresenius Medical Care Holdings, Inc. | Systems and methods for delivery of peritoneal dialysis (PD) solutions with integrated inter-chamber diffuser |
US10842714B2 (en) | 2010-10-14 | 2020-11-24 | Fresenius Medical Care Holdings, Inc. | Systems and methods for delivery of peritoneal dialysis (PD) solutions with integrated inter chamber diffuser |
Also Published As
Publication number | Publication date |
---|---|
JP3213271B2 (en) | 2001-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4630727A (en) | Container for a bicarbonate containing fluid | |
US6645191B1 (en) | Multi-chamber container with a concentrated glucose compartment and a concentrated hydrochloric acid compartment | |
KR100304846B1 (en) | Package for container of liquid medicine containing bicarbonate and ph indicator | |
JP3623294B2 (en) | Medical container containing electrolyte and method for producing the same | |
JP4607609B2 (en) | Chemical solution bag, chemical solution bag container, and method for manufacturing chemical solution bag container | |
JP3213271B2 (en) | Method for producing medical container containing medical solution containing carbonic acid component | |
JPWO2004108059A1 (en) | Aseptic formulation | |
JPH114872A (en) | Medical container | |
JPH119659A (en) | Medical vessel | |
JPH10277132A (en) | Container for medical use | |
JPH10201821A (en) | Container for medical treatment | |
JPH09110703A (en) | Electrolyte infusion and vessel therefor | |
JP7548901B2 (en) | Container for cardioplegic solution containing bicarbonate ion and method for producing same | |
JP3832458B2 (en) | Multi-chamber container for filtration type artificial kidney replacement fluid | |
JP3733583B2 (en) | Bicarbonate-containing chemical solution-filled container package | |
JP2009285318A (en) | Packaging form of gas barrier container | |
JP2002085518A (en) | Double package container housing vitamin b1 or the like- containing aqueous medicine | |
JPH09193963A (en) | Wrapping method of resin container filled with carbonate or bicarbonate | |
JP2006020657A (en) | Trace element-blended infusion preparation | |
JP3904030B2 (en) | Multi-chamber container formulation containing replacement fluid | |
JP2789448B2 (en) | Medical container and manufacturing method thereof | |
JP2000016484A (en) | Plastic container receiving carbonic acid ingredient and manufacture thereof | |
JPH10201820A (en) | Container for medical treatment | |
JPH09108309A (en) | Sterile wrapping of medical container | |
JPH09226842A (en) | Package structure of plastic container receiving bicarbonate or the like |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
LAPS | Cancellation because of no payment of annual fees |